Back to top
more

Amicus Therapeutics (FOLD)

(Delayed Data from NSDQ)

$10.71 USD

10.71
5,091,023

-0.03 (-0.23%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $10.70 -0.01 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates

Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -83.33% and 0.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why

Sales of Amicus' (FOLD) lead drug, Galafold, are rising consistently. Also, the recent approval of the Pompe disease drug combination, Pombiliti + Opfolda, is a positive.

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.

Amicus (FOLD) Banks on Galafold, Overdependence a Concern

Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.

Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated

Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates. The company tightens Galafold revenue guidance for 2023.

Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Synlogic, Inc. (SYBX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug

Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.

Zacks.com featured highlights include Amicus Therapeutics, Genius Sports and Viad

Amicus Therapeutics, Genius Sports and Viad are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Stocks Worth a Watch for Solid Earnings Acceleration

Some of the notable companies to have witnessed solid earnings acceleration as of now are Amicus Therapeutics (FOLD), Genius Sports (GENI) and Viad (VVI).

Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss

FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.

bluebird (BLUE) Q2 Earnings Top, Zynteglo & Skysona Fuel Revenues

bluebird bio (BLUE) reports better-than-expected results in the second quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).

Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance

Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.

Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25% and 5.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks.com featured highlights include First Watch Restaurant Group, VersaBank and Amicus Therapeutics

First Watch Restaurant Group, VersaBank and Amicus Therapeutics are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Top Breakout Stocks to Invest in for Excellent Returns

First Watch Restaurant Group (FWRG), VersaBank (VBNK), and Amicus Therapeutics (FOLD) have been selected as the breakout stocks for today.

Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug

Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease.

Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Company News for May 11, 2023

Companies in The news Are: VSH,COHRICL,FOLD

Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow

Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.